More PHO Phase III Metvix data

Photocure (OSE:PHO) said its Metvix photodynamic therapy cleared 89% of 165 basal cell carcinoma (BCC) lesions in 102 patients at 3 months post-treatment in an Australian Phase III trial. PHO said the response was verified histologically. The trial included patients with large lesions, lesions in the face and ear, and patients with a high risk of surgical complications and poor cosmetic outcome following lesion removal.

Cosmetic outcome in the trial was rated "good or excellent" in 65% of patients. PHO said it will follow the patients for the next 5 years. ...